Collegium Pharmaceutical Inc banner

Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 32.59 USD 0.87% Market Closed
Market Cap: $1B

During the last 3 months Collegium Pharmaceutical Inc insiders have not bought any shares, and sold 2.6m USD worth of shares. The stock price has dropped by 31% over this period (open performance analysis).

The last transaction was made on Mar 18, 2026 by Dieter David , who sold 488.1k USD worth of COLL shares.

Last Transactions:
Dieter David
$-488.1k
Dieter David
$-228.1k
Dreyer Scott
$-1.9m
Dreyer Scott
$-532.8k
Balice-Gordon Rita J.
$-171.7k
Fallon John A.
$-1.6m
Tupper Colleen
$-1m
Smith Thomas B
$-671.6k
Dreyer Scott
$-626.2k
Santini Gino
$-201k
Dreyer Scott
$-184.9k
Rubric Capital Management Lp
$-946.3k
Freund John Gordon
$-400.6k
Freund John Gordon
$-202.1k
Tupper Colleen
$-192.1k
Dreyer Scott
$-567k
Tupper Colleen
$-36.2k
Dreyer Scott
$-57.8k
Tupper Colleen
$-29.3k
Dreyer Scott
$-67.7k
Dreyer Scott
$-461.7k
Tupper Colleen
$-313.4k
Dreyer Scott
$-70.4k
Tupper Colleen
$-45.1k
Dreyer Scott
$-461.7k
Tupper Colleen
$-58.5k
Dreyer Scott
$-98.9k
Kuhlmann Shirley R.
$-742.9k
Kuhlmann Shirley R.
$-560.5k
Kuhlmann Shirley R.
$-1.1m
Kuhlmann Shirley R.
$-703.4k
Smith Thomas B
$-351.3k
View All Transactions

During the last 3 months Collegium Pharmaceutical Inc insiders have not bought any shares, and sold 2.6m USD worth of shares. The stock price has dropped by 31% over this period (open performance analysis).

The last transaction was made on Mar 18, 2026 by Dieter David , who sold 488.1k USD worth of COLL shares.

Sold
0-3
months
2.6m USD
2
3-6
months
3.4m USD
4
6-9
months
3m USD
5
9-12
months
202.1k USD
1
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Collegium Pharmaceutical Inc
Insider Trading Chart

Collegium Pharmaceutical Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Collegium Pharmaceutical Inc
Last Insider Transactions

Global
Insiders Monitor

Collegium Pharmaceutical Inc
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

COLL Intrinsic Value
56.26 USD
Undervaluation 42%
Intrinsic Value
Price $32.59

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett